NANOSNET

 View Only
Expand all | Collapse all

UPFRONT

  • 1.  UPFRONT

    Posted 5 days ago
    Just a reminder- a few of you have started cases, please do complete them and send to me, as we strive to publish at least two cases per quarter.  And if you have an idea for an UPFRONT Case, just email me a few sentences describing it so we can make sure it seems appropriate for the goals of the series (to interest med students and especially neurology and ophthalmology residents in what we do)>


  • 2.  RE: UPFRONT

    Posted 5 days ago
    Larry, 
    I forgot about this. I have an excellent case of chiasma visual loss from a man who developed TB abscesses in the spine from BCG bladder treatments for Bladder Cancer and was placed on extremely high doses of Ethambutol as part of his triple antibiotic regimen. I am treating him now.





  • 3.  RE: UPFRONT

    Posted 5 days ago
    Maybe after you have outcomes?  Would you be able to make it interactive?  Our goal is to show how we can make a difference in a patient's care





  • 4.  RE: UPFRONT

    Posted 5 days ago
    Yes my follow up is in a few weeks which may be too early. Making it interactive is easy as this is a good example of how Ethambutol toxicity can be chiasmal in location and therefore central 10-2 is important. 
    Scott







  • 5.  RE: UPFRONT

    Posted 5 days ago
    Indeed.

    I have a case of chismitis secondary to ethambutol toxicity and beautifully evolving RGC loss after acute onset.
    BW
    Neri




  • 6.  RE: UPFRONT

    Posted 5 days ago
    Hi Neringa,

    How do you know it's chiasmatic?  Bilateral central scotomas with some preferential temporal loss in ethambutol toxicity has an explanation other than a chiasmatic location.  And check how pure the respect for the vertical really is.  

    Ethambutol toxicity affects the smallest PMB fibers.  Those that course nasally to the disc are smaller than those that arc around the fovea.  If the former are more adversely involved, you will get more temporal and less nasal field loss.  

    Alfredo





  • 7.  RE: UPFRONT

    Posted 5 days ago
    And how did you treat this "beautifully evolving" visual loss??!

    ScottForman, MD





  • 8.  RE: UPFRONT

    Posted 5 days ago

    I think she was one of two cases (it has been >1 decade) where we talked with Alfredo, who suggested double dose of AREDS to supplement copper and zinc.





  • 9.  RE: UPFRONT

    Posted 5 days ago
    Yes, ethambutol is a chelator that produces a mitochondrial optic neuropathy by consuming the iron, zinc and copper that the mitochondrial ribosomes use.  It's usually the zinc and copper that's hardest to supplement which is why Emily Chu included them on the AREDS formula.  We proved the rescue in a rat RGC model of the disease.  

    Y H Yoon K H JungA A SadunH C ShinJ Y Koh  Toxicol Appl Pharmacol. 
    2000 Jan 15;162(2):107-14.
     doi: 10.1006/taap.1999.8846.

    Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc

    Best,

    Alfredo  






  • 10.  RE: UPFRONT

    Posted 5 days ago
    And incidentally, both of my cases who I think were caught fairly early, had complete restitution of their visual field function
    Sent from my iPhone





  • 11.  RE: UPFRONT

    Posted 5 days ago
    Presented with visual fields suggestive of bitemporal loss and central field defect overlap. OCT gave minor hint of hemifield RGC loss in the left eye (right looked normal) and over time this has progressed to binasal hemifield RGC loss with preserved pRNFL (next time I am planning to include NSITE as that may capture very localised PMB loss).

    MRI: atrophy of chiasm, with remaining optic nerves looking preserved

    Treatment: stopped ethambuthol, rifampicin and clarithromycin. (has been for 10 months prior symptoms onset). 
    Visual function has improved.
    BW
    N

    Sent from my iPhone





  • 12.  RE: UPFRONT

    Posted 4 days ago
    Thank you Alfredo for the correct explanation for the "chiasma" looking field defects commonly seen in Ethambutol toxicity.  I wonder why the predilection for small PMB fibers. More Zinc?
    +=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=
    Scott Forman, MD
    Senior Fellow North American Neuro-ophthalmology Society

    Adult and Pediatric Neuro-ophthalmology
    Comprehensive Ophthalmology
    Functional Medicine














  • 13.  RE: UPFRONT

    Posted 2 days ago
    Hi Scott,

    Good question.  For all mitochondrial optic neuropathies (MON -- LHON, DOA, copper deficiency, ethambutol, etc.) the issue comes down to surface area to volume ratios.  The surface area of a fiber represents the workload as the membrane needs constant ATP to fuel the sodium/potassium pumps that restore the membrane potential.  But the volume represents the capacity to contain mitochondria.  If a fiber has twice the diameter, it has 4 times the surface area but 8 times the volume and hence a more favorable ratio.  All our histopathology shows a steady march in MON from smallest fibers to larger ones.  --Alfredo   Eg.  

    Pan BX, Ross-Cisneros FN, Carelli V, Rue KS, Salomao SR, Moraes-Filho MN, Moraes MN, Berezovsky A, Belfort R Jr, Sadun AA.Mathematically modeling the involvement of axons in Leber's hereditary optic neuropathy.
    Invest Ophthalmol Vis Sci. 2012 Nov 9;53(12):7608-17. doi: 10.1167/iovs.12-10452.